Human CJC-1295 research
The blood measurements are interesting enough without a medal being hung on them.
GH / IGF-1 findings
The core CJC-1295 human work asked how strongly and how long the hormone system responded. Teichman and colleagues studied healthy adults. After single subcutaneous doses of 30 or 60 micrograms per kilogram, mean growth hormone rose 2- to 10-fold for 6 days or more; IGF-1 rose 1.5- to 3-fold for 9-11 days. After multiple doses, IGF-1 remained above baseline up to 28 days. These are study administrations, reported to identify the experiment.
I credit the sustained activity to a well-defined human experiment. Its ambitions were pharmacological: characterising what happened to the compound and the hormone response. There were no race times, recovery scores or longevity outcomes to celebrate.
Pulses during sustained stimulation
For healthy men aged 20 to 40, the Ionescu and Frohman study supplies a different observation. Basal growth hormone rose approximately 7.5-fold, mean growth hormone by about 46 percent and IGF-1 by about 45 percent one week later, while pulse frequency and magnitude were unaltered.
That result complicates a picture of growth hormone simply sitting at a higher, flat level. The underlying pulses survived the stimulation. I admire that specificity: a study of the pattern of secretion tells a more exact story than the usual claim that the compound “boosts” a hormone.
Serum protein changes
In 11 healthy young men, the serum protein profile shifted after CJC-1295. Apolipoprotein A1 and a transthyretin isoform decreased; a C-terminal albumin fragment and immunoglobulin species increased. The immunoglobulin/albumin-fragment signal tracked linearly with IGF-1, making those changes candidate biomarkers of GH/IGF-1 activation.
A biomarker is a measurable sign of a biological process. The word “candidate” matters here: these protein changes were clues to activity. They did not measure muscle gained or time saved in training.
The peptide design
CJC-1295 acts at the GHRH receptor on growth-hormone-producing cells in the anterior pituitary. The receptor activates intracellular signalling that promotes GH production and release; GH then stimulates IGF-1 production in the liver. The GHRH pharmacology review describes this signalling family.
The molecule's hGRF(1-29) backbone has four substitutions: D-Ala at position 2, Gln at 8, Ala at 15 and Leu at 27. They improve resistance to breakdown. For the long-acting form, the extra DAC handle joins it to albumin. In rats, the albumin-conjugating design increased growth-hormone exposure and remained detectable beyond 72 hours. In GHRH-knockout mice, CJC-1295 normalised growth under the study conditions. Those animal experiments establish their own findings; human performance claims require human outcomes.
CJC-1295 and ipamorelin
The combination has a clear receptor rationale. CJC-1295 acts through the GHRH receptor; ipamorelin acts through the ghrelin/growth-hormone-secretagogue receptor. The GHRH-analog review provides the wider pharmacological context. Experimental work on GHRH and growth-hormone-releasing peptides supports a greater-than-additive GH response through these distinct receptors.
I accept the receptor rationale; a controlled outcome trial of the actual pairing remains overdue. The record here contains no controlled human CJC-1295/ipamorelin trials establishing body-composition, performance or anti-aging benefits. Community enthusiasm for a combination cannot assign the credit between its ingredients.